Maligne Hyperthermie: Diagnostik konkret

Zusammenfassung

Sowohl in der präoperativen Visite als auch bei intraoperativ verdächtigen Zwischenfällen kann sich die Frage nach einer Abklärung auf maligne Hyperthermie ergeben. Heute stehen mit molekulargenetischen Methoden und mit der Muskelbiopsie und Kontrakturtest 2 grundsätzliche verschiedene Testmethoden zur Verfügung. Beide diagnostischen Methoden haben Vor- und Nachteile – und ergänzen sich.

Abstract

Testing for malignant hyperthermia (MH) susceptibility is usually performed either in relatives of MH susceptible persons or in patients with an MH suspicious clinical event. There are two diagnostic options: muscle biopsy with in-vitro contracture testing and molecular genetic diagnosis. Patients with familial MH mutations are usually tested genetically. A genetic screening can be performed in clinical events with a high pretest probability. MH susceptibility can be confirmed by presence of a diagnostic MH mutation. Absence of MH mutations cannot exclude MH. The only option to exclude MH susceptibility is contracture testing

Schlüsselwörter

In-vitro-Kontrakturtest - Ryanodinrezeptor - Maligne-Hyperthermie-Diagnostik

Key words

In-vitro contracture test - ryanodine receptor - malignant hyperthermia diagnostics

• Literatur

• 1 Johannsen S, Schuster F. Maligne Hyperthermie: Pathophysiologie, Diagnostik und Therapie. Anasthesiol Intensivmed Notfallmed Schmerzther 2019; 54: 527-537
• 2 Larach MG, Localio AR, Allen GC. et al. A clinical grading scale to predict malignant hyperthermia susceptibility. Anesthesiology 1994; 80: 771-779
• 3 Frei D, Stowell KM, Langton EE. et al. Administration of anaesthetic triggering agents to patients tested malignant hyperthermia normal and their relatives in New Zealand: an update. Anaesth Intensive Care 2017; 45: 611-618
• 4 Hopkins PM, Rüffert H, Snoeck MM. et al. European Malignant Hyperthermia Group guidelines for investigation of malignant hyperthermia susceptibility. Br J Anaesth 2015; 115: 531-539
• 5 Allen GC, Larach MG, Kunselman AR. The sensitivity and specificity of the caffeine-halothane contracture test: a report from the North American Malignant Hyperthermia Registry. The North American Malignant Hyperthermia Registry of MHAUS. Anesthesiology 1998; 88: 579-588
• 6 Ording H, Brancadoro V, Cozzolino S. et al. In vitro contracture test for diagnosis of malignant hyperthermia following the protocol of the European MH Group: results of testing patients surviving fulminant MH and unrelated low-risk subjects. The European Malignant Hyperthermia Group. Acta Anaesthesiol Scand 1997; 41: 955-966
• 7 MacLennan DH, Duff C, Zorzato F. et al. Ryanodine receptor gene is a candidate for predisposition to malignant hyperthermia. Nature 1990; 343: 559-561
• 8 McCarthy TV, Healy JM, Heffron JJ. et al. Localization of the malignant hyperthermia susceptibility locus to human chromosome 19q12-13.2. Nature 1990; 343: 562-564
• 9 Levano S, Gonzalez A, Singer M. et al. Resequencing array for gene variant detection in malignant hyperthermia and butyrylcholinestherase deficiency. Neuromuscul Disord 2017; 27: 492-499
• 10 Miller DM, Daly C, Aboelsaod EM. et al. Genetic epidemiology of malignant hyperthermia in the UK. Br J Anaesth 2018; 121: 944-952
• 11 Girard T, Treves S, Voronkov E. et al. Molecular genetic testing for malignant hyperthermia susceptibility. Anesthesiology 2004; 100: 1076-1080
• 12 Robinson RL, Anetseder MJ, Brancadoro V. et al. Recent advances in the diagnosis of malignant hyperthermia susceptibility: how confident can we be of genetic testing. Eur J Hum Genet 2003; 11: 342-348
• 13 Rüffert H, Wehner M, Deutrich C. et al. Maligne Hyperthermie. Anaesthesist 2007; 56: 923-929
• 14 Adam H, Gottschaldt U, Pausch NC. et al. Fulminante Maligne Hyperthermie: Untypischer Verlauf während der 9. Allgemeinanästhesie. Anasthesiol Intensivmed Notfallmed Schmerzther 2007; 42: 692-699
• 15 Klingler W, Roewer N, Schuster F. et al. Therapie der malignen Hyperthermie: S1-Leitlinie. Anästh Intensivmed 2018; 59: 204-208